<DOC>
	<DOCNO>NCT01320436</DOCNO>
	<brief_summary>Ulcerative colitis ( UC ) chronic inflammatory disease result increased morbidity patient . The current standard treatment mild moderate UC ( MTMUC ) include 5-aminosalicylic compound ( 5ASA ) olsalazine mesalamine , yet patient continue experience disease symptom flare-up . These patient require high dosage 5ASA medication many case escalate steroid and/or immunosuppressant therapy comprise high risk hazardous side effect . Curcumin , active ingredient Indian herb Rhizoma Curcuma Longa , extensively study context inflammatory disease . In human , control study use curcumin adjust therapy 5ASA medication show superior placebo maintain remission MTMUC patient . A small , preliminary open label study also show efficacy reduce disease symptom inflammatory marker group patient . This data provide base investigate integrative approach optimize current standard treatment MTMUC patient . We speculate use combine therapy 5ASA medication curcumin could benefit subgroup patient reduce morbidity perhaps need escalate pharmacological intervention .</brief_summary>
	<brief_title>Curcumin + Aminosalicylic Acid ( 5ASA ) Versus 5ASA Alone Treatment Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Diagnosis UC confirm endoscopic histologic criterion establish RomeIII Disease activity score &gt; 5 â‰¤13 accord Simple clinical colitis activity index ( SCCAI ) Patient stable 5 ASA medication dose least 4 week prior inclusion Patients receive immunosuppressant biological therapy ( azathioprine , 6mercaptopurine , infliximab methotrexate ) must stable dose least 3 month prior inclusion Patients receive topical therapy ( 5ASA steroidal ) , must stable dose least 2 week prior inclusion Patient hemoglobin &gt; 10 g/dl . Able willing give write consent Patient renal liver disease , sever cardiovascular disease , chronic pancreatitis , diabetes mellitus gallstone . Patient laboratory abnormality indicate anemia ( hemoglobin &lt; 10 ) , leucopenia , thrombocytopenia , abnormal coagulation . Patient infection , sepsis pneumonia . Pregnant nursing woman . Unable unwilling receive CURCUMIN therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Curcumin</keyword>
</DOC>